{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:57:57Z","timestamp":1791622677944,"version":"4.3.4"},"reference-count":104,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Menin inhibitors are targeted therapies for the treatment of genetically defined subsets of acute leukemia. The menin inhibitor revumenib is approved for the treatment of relapsed or refractory leukemia with rearrangement of KMT2A. In addition, multiple menin inhibitors are currently in clinical development aimed at targeting other additional subsets, such as NPM1 mutations, which form up to 30% of acute myeloid leukemia. However, as observed with other targeted therapies for cancer, on-target resistance mutations emerged in advanced cases following monotherapy. Therefore, combination strategies incorporating menin inhibitors are needed to improve durability and depth of remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Menin inhibitors have the potential to reshape treatment paradigms in acute leukemia. There are multiple promising preclinical combinations that require careful clinical trial design and implementation for a successful translation into the clinical setting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-24-0212","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T14:01:51Z","timestamp":1756908111000},"page":"547-560","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Combination Strategies with Menin Inhibitors for Acute Leukemia"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas C.","family":"Issa","sequence":"first","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-887X","authenticated-orcid":false,"given":"Sheng F.","family":"Cai","sequence":"additional","affiliation":[{"name":"2Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-2745","authenticated-orcid":false,"given":"Alex","family":"Bataller","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-9390","authenticated-orcid":false,"given":"Eytan M.","family":"Stein","sequence":"additional","affiliation":[{"name":"2Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2025,9,3]]},"reference":[{"key":"2025110303124681400_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"2025110303124681400_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"key":"2025110303124681400_bib3","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"2025110303124681400_bib4","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"2025110303124681400_bib5","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"key":"2025110303124681400_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025110303124681400_bib7","unstructured":"Syndax Pharmaceuticals\n          . REVUFORJ\u00ae(Revumenib) prescribing information; Syndax Pharmaceuticals. [cited 2025 Aug 25]. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/218944s000lbl.pdf."},{"key":"2025110303124681400_bib8","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"2025110303124681400_bib9","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"2025110303124681400_bib10","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.tibs.2013.05.005","article-title":"Menin: a scaffold protein that controls gene expression and cell signaling","volume":"38","author":"Matkar","year":"2013","journal-title":"Trends Biochem Sci"},{"key":"2025110303124681400_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1126\/science.adc9318","article-title":"Menin \u201creads\u201d H3K79me2 mark in a nucleosomal context","volume":"379","author":"Lin","year":"2023","journal-title":"Science"},{"key":"2025110303124681400_bib12","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/leu.2015.6","article-title":"Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells","volume":"29","author":"Spencer","year":"2015","journal-title":"Leukemia"},{"key":"2025110303124681400_bib13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1128\/MCB.21.1.224-234.2001","article-title":"Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia","volume":"21","author":"Thorsteinsdottir","year":"2001","journal-title":"Mol Cell Biol"},{"key":"2025110303124681400_bib14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/378505a0","article-title":"Altered Hox expression and segmental identity in Mll-mutant mice","volume":"378","author":"Yu","year":"1995","journal-title":"Nature"},{"key":"2025110303124681400_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/nrc2253","article-title":"MLL translocations, histone modifications and leukaemia stem-cell development","volume":"7","author":"Krivtsov","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"2025110303124681400_bib16","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1182\/bloodadvances.2018025866","article-title":"HoxA9 transforms murine myeloid cells by a feedback loop driving expression of key oncogenes and cell cycle control genes","volume":"2","author":"Zhong","year":"2018","journal-title":"Blood Adv"},{"key":"2025110303124681400_bib17","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.molcel.2022.02.013","article-title":"MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape","volume":"82","author":"Olsen","year":"2022","journal-title":"Mol Cell"},{"key":"2025110303124681400_bib18","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib19","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/0008-5472.CAN-06-2369","article-title":"Interaction of MLL amino terminal sequences with menin is required for transformation","volume":"67","author":"Caslini","year":"2007","journal-title":"Cancer Res"},{"key":"2025110303124681400_bib20","doi-asserted-by":"crossref","first-page":"31742","DOI":"10.1074\/jbc.M111.258186","article-title":"Crystal structure of menin reveals binding site for mixed lineage leukemia (MLL) protein","volume":"286","author":"Murai","year":"2011","journal-title":"J Biol Chem"},{"key":"2025110303124681400_bib21","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature10806","article-title":"The same pocket in menin binds both MLL and JUND but has opposite effects on transcription","volume":"482","author":"Huang","year":"2012","journal-title":"Nature"},{"key":"2025110303124681400_bib22","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41375-023-01877-1","article-title":"The KMT2A recombinome of acute leukemias in 2023","volume":"37","author":"Meyer","year":"2023","journal-title":"Leukemia"},{"key":"2025110303124681400_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"key":"2025110303124681400_bib24","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.leu.2404808","article-title":"Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias","volume":"21","author":"Mullighan","year":"2007","journal-title":"Leukemia"},{"key":"2025110303124681400_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"2025110303124681400_bib26","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib27","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib28","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.2021012806","article-title":"The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML","volume":"139","author":"Heikamp","year":"2022","journal-title":"Blood"},{"key":"2025110303124681400_bib29","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/s41375-021-01146-z","article-title":"Menin is necessary for long term maintenance of meningioma-1 driven leukemia","volume":"35","author":"Libbrecht","year":"2021","journal-title":"Leukemia"},{"key":"2025110303124681400_bib30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib31","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1056\/NEJMc2404110","article-title":"Response and resistance to menin inhibitor in UBTF tandem duplication AML","volume":"390","author":"Tiong","year":"2024","journal-title":"N Engl J Med"},{"key":"2025110303124681400_bib32","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/s41375-021-01309-y","article-title":"Therapeutic implications of menin inhibition in acute leukemias","volume":"35","author":"Issa","year":"2021","journal-title":"Leukemia"},{"key":"2025110303124681400_bib33","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"2025110303124681400_bib34","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1182\/blood-2024-207106","article-title":"Bleximenib dose optimization and determination of RP2D from a phase 1 study in relapsed\/refractory acute leukemia patients with KMT2A and NPM1 alterations","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood-2024-194384","article-title":"Updated results and longer follow-up from the AUGMENT-101 phase 2 study of revumenib in all patients with relapsed or refractory (R\/R) KMT2Ar acute leukemia","volume":"144","author":"Aldoss","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1182\/blood-2024-194827","article-title":"Phase 1 results: first-in-human phase 1\/2 study of the menin-MLL inhibitor enzomenib (DSP-5336) in patients with relapsed or refractory acute leukemia","volume":"144","author":"Zeidner","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib37","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2024-198959","article-title":"A first-in-human phase 1\/2 study of the menin-KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia","volume":"144","author":"Wu","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib38","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood-2023-173149","article-title":"Covalent menin inhibitor Bmf-219 in patients with relapsed or refractory (R\/R) acute leukemia (AL): preliminary phase 1 data from the covalent-101 study","volume":"142","author":"Lancet","year":"2023","journal-title":"Blood"},{"key":"2025110303124681400_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41408-021-00557-6","article-title":"Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J"},{"key":"2025110303124681400_bib40","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1182\/bloodadvances.2022008316","article-title":"Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML","volume":"7","author":"Issa","year":"2023","journal-title":"Blood Adv"},{"key":"2025110303124681400_bib41","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/bloodadvances.2021006489","article-title":"Molecular profile of FLT3-mutated relapsed\/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib","volume":"6","author":"Smith","year":"2022","journal-title":"Blood Adv"},{"issue":"Suppl 16","key":"2025110303124681400_bib42","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1200\/JCO.2025.43.16_suppl.6506","article-title":"Ziftomenib in relapsed\/refractory (R\/R) NPM1-mutant acute myeloid leukemia (AML): phase 1b\/2 clinical activity and safety results from the pivotal KOMET-001 study","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"2025110303124681400_bib43","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"2025110303124681400_bib44","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","article-title":"Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia","volume":"33","author":"McNeer","year":"2019","journal-title":"Leukemia"},{"key":"2025110303124681400_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-024-01066-y","article-title":"The landscape of NUP98 rearrangements clinical characteristics and treatment response from 1491 acute leukemia patients","volume":"14","author":"Tian","year":"2024","journal-title":"Blood Cancer J"},{"key":"2025110303124681400_bib46","article-title":"Revumenib activity in patients with acute leukemia with NUP98r: results from the AUGMENT-101 phase 1 study","author":"Issa","year":"2025"},{"key":"2025110303124681400_bib47","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"2025110303124681400_bib48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","article-title":"Functional heterogeneity of genetically defined subclones in acute myeloid leukemia","volume":"25","author":"Klco","year":"2014","journal-title":"Cancer Cell"},{"key":"2025110303124681400_bib49","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"2025110303124681400_bib50","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2024-199170","article-title":"Ziftomenib combined with venetoclax\/azacitidine in relapsed\/refractory NPM1-m or KMT2A-r acute myeloid leukemia: interim phase 1a results from KOMET-007","volume":"144","author":"Fathi","year":"2024","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib51","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2024-207072","article-title":"Phase 1b study of menin-KMT2A inhibitor bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations","volume":"144","author":"Recher","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib52","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1200\/JCO-25-00914","article-title":"Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML","volume":"43","author":"Zeidner","year":"2025","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2025110303124681400_bib53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/blood-2024-204375","article-title":"Phase I\/II study of the all-oral combination of revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax (SAVE) in R\/R AML","volume":"144","author":"Issa","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib54","first-page":"e104","article-title":"Safety and activity of revumenib in combination with fludarabine\/cytarabine (FLA) in patients with relapsed\/refractory acute leukemias","volume":"8","author":"Shukla","year":"2024","journal-title":"HemaSphere"},{"key":"2025110303124681400_bib55","article-title":"Ziftomenib combined with intensive induction chemotherapy (7 + 3) in newly diagnosed NPM1-m or KMT2A-r acute myeloid leukemia (AML): updated phase 1A\/B results from KOMET-007","author":"Erba","year":"2025"},{"key":"2025110303124681400_bib56","article-title":"RP2D determination of bleximenib in combination with VEN + AZA: phase 1b study in ND & R\/R AML with KMT2A\/NPM1 alterations","author":"Wei","year":"2025"},{"key":"2025110303124681400_bib57","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"2025110303124681400_bib58","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2008-01-135012","article-title":"Menin regulates the function of hematopoietic stem cells and lymphoid progenitors","volume":"113","author":"Maillard","year":"2009","journal-title":"Blood"},{"key":"2025110303124681400_bib59","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"2025110303124681400_bib60","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ng0897-375","article-title":"Somatic mutation of the MEN1 gene in parathyroid tumours","volume":"16","author":"Heppner","year":"1997","journal-title":"Nat Genet"},{"key":"2025110303124681400_bib61","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"2025110303124681400_bib62","doi-asserted-by":"crossref","first-page":"107777","DOI":"10.1016\/j.jbc.2024.107777","article-title":"Drug-resistant menin variants retain high binding affinity and interactions with MLL1","volume":"300","author":"Ray","year":"2024","journal-title":"J Biol Chem"},{"key":"2025110303124681400_bib63","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"2025110303124681400_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"2025110303124681400_bib65","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"Suppl 1","key":"2025110303124681400_bib66","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood-2024-208887","article-title":"Discerning the landscape of menin inhibitor resistance","volume":"144","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin\u2013MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib68","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood.2023023644","article-title":"Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib69","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.2024024310","article-title":"Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML","volume":"144","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib70","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025110303124681400_bib71","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3026(23)00089-3","article-title":"Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial","volume":"10","author":"D\u00f6hner","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025110303124681400_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1507471","article-title":"Assessment of minimal residual disease in standard-risk AML","volume":"374","author":"Ivey","year":"2016","journal-title":"N Engl J Med"},{"key":"2025110303124681400_bib73","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1001\/jama.2023.1363","article-title":"DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant","volume":"329","author":"Dillon","year":"2023","journal-title":"JAMA"},{"key":"2025110303124681400_bib74","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/blood.2023021579","article-title":"Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib75","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.2023023096","article-title":"Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission","volume":"143","author":"Othman","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib76","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1038\/s41467-019-09745-2","article-title":"Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation","volume":"10","author":"Cocciardi","year":"2019","journal-title":"Nat Commun"},{"key":"2025110303124681400_bib77","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1182\/blood-2013-01-479188","article-title":"Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia","volume":"122","author":"Kr\u00f6nke","year":"2013","journal-title":"Blood"},{"key":"2025110303124681400_bib78","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood.2021011917","article-title":"Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1\/FLT3-mutated AML","volume":"138","author":"Carter","year":"2021","journal-title":"Blood"},{"key":"2025110303124681400_bib79","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"key":"2025110303124681400_bib80","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood.2023022480","article-title":"Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias","volume":"144","author":"Kwon","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib81","first-page":"1278","article-title":"Bleximenib, the novel menin-KMT2A inhibitor JNJ-75276617, impairs long-term proliferation and immune evasion in acute myeloid leukemia","volume":"110","author":"Hogeling","year":"2025","journal-title":"Haematologica"},{"key":"2025110303124681400_bib82","first-page":"258","article-title":"Targeting Menin disrupts the KMT2A\/B and polycomb balance to paradoxically activate bivalent genes","volume":"25","author":"Sparbier","year":"2023","journal-title":"Nat Cell Biol"},{"key":"2025110303124681400_bib83","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"2025110303124681400_bib84","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1182\/blood.2020005037","article-title":"Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition","volume":"136","author":"Dzama","year":"2020","journal-title":"Blood"},{"key":"2025110303124681400_bib85","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1182\/blood.2020006575","article-title":"Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations","volume":"136","author":"Miao","year":"2020","journal-title":"Blood"},{"key":"2025110303124681400_bib86","first-page":"2513","article-title":"Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1\/FLT3-ITD\/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model","volume":"108","author":"Carter","year":"2023","journal-title":"Haematologica"},{"key":"2025110303124681400_bib87","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/s43018-022-00366-1","article-title":"IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia","volume":"3","author":"Aubrey","year":"2022","journal-title":"Nat Cancer"},{"key":"2025110303124681400_bib88","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1182\/blood.2023021105","article-title":"Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML","volume":"143","author":"Bourgeois","year":"2024","journal-title":"Blood"},{"key":"2025110303124681400_bib89","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-023-00826-6","article-title":"Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1","volume":"13","author":"Fiskus","year":"2023","journal-title":"Blood Cancer J"},{"key":"2025110303124681400_bib90","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41375-023-01882-4","article-title":"Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1","volume":"37","author":"Mill","year":"2023","journal-title":"Leukemia"},{"key":"2025110303124681400_bib91","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"issue":"Suppl 1","key":"2025110303124681400_bib92","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1182\/blood-2022-168834","article-title":"Combination of menin and IDH mutant inhibition in acute myeloid leukemia","volume":"140","author":"Yoon","year":"2022","journal-title":"Blood"},{"key":"2025110303124681400_bib93","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-1772","article-title":"KAT6A and KAT7 histone acetyltransferase complexes are molecular dependencies and therapeutic targets in NUP98-rearranged acute myeloid leukemia","author":"Michmerhuizen","year":"2025  19","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukemia","author":"Gordon","year":"2025  19","journal-title":"Cancer Discov"},{"key":"2025110303124681400_bib95","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1016\/j.celrep.2015.12.003","article-title":"MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199","volume":"13","author":"Benito","year":"2015","journal-title":"Cell Rep"},{"key":"2025110303124681400_bib96","first-page":"6572","article-title":"Mitogenic signalling and substrate specificity of the Flk2\/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells","volume":"13","author":"Dosil","year":"1993","journal-title":"Mol Cell Biol"},{"key":"2025110303124681400_bib97","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood.V99.1.310","article-title":"FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model","volume":"99","author":"Kelly","year":"2002","journal-title":"Blood"},{"key":"2025110303124681400_bib98","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"key":"2025110303124681400_bib99","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"key":"2025110303124681400_bib100","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"2025110303124681400_bib101","doi-asserted-by":"crossref","first-page":"e935","DOI":"10.1097\/HS9.0000000000000935","article-title":"The MLL\u2013menin interaction is a therapeutic vulnerability in NUP98-rearranged AML","volume":"7","author":"Rasouli","year":"2023","journal-title":"HemaSphere"},{"key":"2025110303124681400_bib102","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1038\/s41375-024-02312-9","article-title":"Combination of menin and kinase inhibitors as an effective treatment for leukemia with NUP98 translocations","volume":"38","author":"Miao","year":"2024","journal-title":"Leukemia"},{"key":"2025110303124681400_bib103","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1182\/blood-2017-12-818948","article-title":"The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"2025110303124681400_bib104","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.2020006113","article-title":"Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenografts","volume":"136","author":"Perner","year":"2020","journal-title":"Blood"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0212\/3647026\/bcd-24-0212.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-24-0212\/3658897\/bcd-24-0212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/547\/3663399\/bcd-24-0212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/6\/6\/547\/3663399\/bcd-24-0212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T08:13:13Z","timestamp":1762157593000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/6\/6\/547\/766818\/Combination-Strategies-with-Menin-Inhibitors-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,3]]},"references-count":104,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,9,3]]},"published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-24-0212","relation":{},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,3]]}}}